Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069877 | 0.88 | THRA (0.34) | ESR1CNR2MAOAMAOBALPL | |
| SCHEMBL10069908 | 0.86 | KDM4E (0.32) | ESR1CNR2MAOAMAOBALPL | |
| SCHEMBL10070422 | 0.73 | TLR7 (0.31) | TLR7 | |
| SCHEMBL10070091 | 0.72 | — | — | |
| SCHEMBL10070944 | 0.72 | MMP9 (0.34) | — | |
| SCHEMBL10070428 | 0.71 | — | — | |
| SCHEMBL10070044 | 0.71 | MMP1 (0.32) | TLR7 | |
| SCHEMBL10071001 | 0.71 | SYK (0.35) | MAOAMAOB | |
| SCHEMBL10070426 | 0.71 | ALDH1A1 (0.35) | TLR7HSD17B10 | |
| SCHEMBL10070074 | 0.71 | MAPT (0.40) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012006680-A1 | 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS | AVEXA LIMITED (AU) | 2012-01-19 | — | — | WO | disclosed |